Top

Japanese Encephalitis Vaccine

Active

SPE2DP-19-R-2434Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The Defense Logistics Agency Troop Support is seeking capable sources to supply the Japanese Encephalitis Vaccine (JEV) through a one-year base contract with two additional one-year option periods under an indefinite quantity contract. The anticipated quantities for the base year and options are approximately 420,000 doses (up to 500,000), 320,000 doses (up to 400,000), and 250,000 doses (up to 330,000) respectively, with flexibility based on service requirements. The vaccine required must be FDA licensed, purified, inactivated, Vero Cell culture derived, free of preservatives such as Thimerosal, latex free, suitable for intramuscular use, and approved for individuals two months and older. Doses should be delivered as a sterile 0.5 ml suspension in a pre-filled Type 1 glass syringe with a chlorobutyl elastomer plunger, with or without a separate needle. Interested manufacturers or developers must provide detailed information including their manufacturing location, annual capacity, FDA registration status, product specifications, pricing, inventory, and storage details. Those developing new products should include the development stage and relevant testing information. This request for information aims to gather data to assist DLA Troop Support in planning and procurement strategy for the JEV and does not guarantee a solicitation or contract award. Submitted information will be kept confidential under federal law and the Protected Critical Infrastructure Information Program and should be sent electronically by the specified deadline. The contract falls under NAICS code 325414, and the point of contact for questions and submissions is the contract specialist Danielle Delaney.

General Info

DLA Troop Support seeks FDA-licensed Japanese Encephalitis Vaccine, one-year base plus two option periods.

Agency

N/A

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Not specified

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseSources Sought

PostedMay 22

Sources Sought

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyN/A

Contacts1 person available

OfficeN/A

Organization / Agency

N/A

Office AddressN/A

Contacts

Danielle DelaneyContract Specialist

contact@example.gov

+1 (555) 000-0000

Full Description

The Defense Logistics Agency Troop Support is seeking sources capable of providing the Japanese Encephalitis Vaccine (JEV). DLA Troop Support is contemplating awarding a one-year base with two one-year options, indefinite quantity contract for the JEV. The estimated annual quantity to be ordered for the base year is 420,000 doses (maximum 500,000 doses), 320,000 doses for option year 1 (maximum 400,000 doses), and 250,000 doses for option year 2 (maximum 330,000 doses). However, the quantity may increase or decrease as the Services requirements change. The vaccine shall be purified, inactivated, Vero Cell culture derived, contain no stabilizers, Thimerosal/Preservative free, Latex free, licensed by the Food and Drug Administration (FDA), suitable for intramuscular administration and intended for active immunization against Japanese Encephalitis disease. The vaccine shall be a sterile 0.5 ml suspension in a pre-filled syringe (Type 1 glass) with a plunger stopper (chlorobutyl elastomer) with or without a separate needle. The vaccine must be approved by the FDA for administration to persons 2 months of age and up. Must have FDA approval to sell the JEV before award of the contract. If your firm currently manufactures or distributes the JEV, please provide information with respect to the following: a) Place of manufacture b) Estimated annual capacity c) FDA registration d) Product name and description including description of any special features e) Current unit sale price f) Estimated inventory level and storage requirements *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the JEV or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the JEV. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this RFI may be submitted electronically in pdf format and emailed to danielle.delaney@dla.mil by June 20, 2019.